Table 2 Key performance indices for detection of alterations in classic oncogenic drivers in NSCLC
Patient group | Genomic alterations | Sensitivity (%) | PPV (%) | Specificity (%) | |||
|---|---|---|---|---|---|---|---|
SPU | PLA | SPU | PLA | SPU | PLA | ||
Entire cohort (n = 71) | Drivers | 50.0 | 63.5 | 96.3 | 97.1 | 99.8 | 99.8 |
EGFR | 25.0 | 70.8 | 100 | 100 | 100 | 100 | |
KRAS | 83.3 | 75.0 | 100 | 100 | 100 | 100 | |
ALK | 75.0 | 37.5 | 85.7 | 100 | 98.5 | 100 | |
ROS1 | 66.7 | 66.7 | 100 | 100.0 | 100 | 100 | |
BRAF | 100.0 | 100.0 | 100 | 50.0 | 100 | 99.0 | |
MET | 0.0 | 0.0 | na | na | 100 | 100 | |
RET | 100 | 100 | 100 | 100 | 100 | 100 | |
Centrally located lung tumors (n = 39) | Drivers | 63.0 | 59.3 | 94.4 | 100 | 99.5 | 100 |
EGFR | 25.0 | 75.0 | 100 | 100 | 100 | 100 | |
KRAS | 85.7 | 57.1 | 100 | 100 | 100 | 100 | |
ALK | 71.4 | 28.6 | 83.3 | 100 | 97.1 | 100 | |
ROS1 | 66.7 | 66.7 | 100 | 100 | 100 | 100 | |
BRAF | 100 | 100 | 100 | 100 | 100 | 100 | |
MET | nd | nd | nd | nd | nd | nd | |
RET | 100 | 100 | 100 | 100 | 100 | 100 | |
Smokers (n = 33) | Drivers | 68.8 | 68.8 | 100 | 100 | 100 | 100 |
EGFR | 33.3 | 66.7 | 100 | 100 | 100 | 100 | |
KRAS | 75.0 | 75.0 | 100 | 100 | 100 | 100 | |
ALK | 100 | 0.0 | 100 | na | 100 | 100 | |
ROS1 | 100 | 100 | 100 | 100 | 100 | 100 | |
BRAF | 100 | 100 | 100 | 100 | 100 | 100 | |
MET | 0.0 | 0.0 | na | na | 100 | 100 | |
RET | nd | nd | nd | nd | nd | nd | |
LUSC (n = 15) | Drivers | 100 | 100 | 100 | 100 | 100 | 100 |
EGFR | 100 | 100 | 100 | 100 | 100 | 100 | |
KRAS | nd | nd | nd | nd | nd | nd | |
ALK | 100 | 100 | 100 | 100 | 100 | 100 | |
ROS1 | nd | nd | nd | nd | nd | nd | |
BRAF | nd | nd | nd | nd | nd | nd | |
MET | nd | nd | nd | nd | nd | nd | |
RET | nd | nd | nd | nd | nd | nd | |